Home Newsfeeds Seaport Global Initiates Coverage On SoFi Technologies with Neutral Rating

Seaport Global Initiates Coverage On SoFi Technologies with Neutral Rating

Seaport Global analyst Bill Ryan initiates coverage on SoFi Technologies (NASDAQ:SOFI) with a Neutral rating.

byBenzinga Newsdesk

September 9, 2022

1 minute read

Seaport Global analyst Bill Ryan initiates coverage on SoFi Technologies (NASDAQ:SOFI) with a Neutral rating.

$1000 Invested In Rockwell Automation 20 Years Ago Would Be Worth This Much Today

By Benzinga Insights

July 25, 2:00 PM

Rockwell Automation (NYSE:ROK) has outperformed the market over the past 20 years by 5.75% on an annualized basis…

ROK

Check Out 3 High-Yielding Dividend Stocks In Tech And Telecom Sector From Wall Street’s Most Accurate Analysts

By Lisa Levin

October 5, 8:52 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

CCOI

Diversified Model Drives Double-Digit Returns: Why Annaly Capital Management Earned An Upgrade

By Lekha Gupta

May 2, 3:13 PM

Piper Sandler & Co analyst Crispin Love upgraded Annaly Capital Management Inc (NYSE:NLY) to Overweight from Neutral at a slightly increased price…

NLY

Janssen Presents Efficacy And Subgroup Analyses From MAIA Study Showing Long-Term Results Of DARZALEX (daratumumab)-based Regimen In Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

By Benzinga Newsdesk

December 12, 11:29 AM

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating

JNJ

Seaport Global Initiates Coverage On SoFi Technologies with Neutral Rating

Related Posts

$1000 Invested In Rockwell Automation 20 Years Ago Would Be Worth This Much Today

Check Out 3 High-Yielding Dividend Stocks In Tech And Telecom Sector From Wall Street’s Most Accurate Analysts

Diversified Model Drives Double-Digit Returns: Why Annaly Capital Management Earned An Upgrade

Janssen Presents Efficacy And Subgroup Analyses From MAIA Study Showing Long-Term Results Of DARZALEX (daratumumab)-based Regimen In Newly Diagnosed, Transplant-Ineligible Multiple Myeloma